Related Experiment Video
Updated: Sep 10, 2026

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution
Published on: July 4, 2014
Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl
I Katzhendler1, R Azoury, M Friedman
1Department of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, Israel.
Abstract:
The influence of hydroxypropyl methylcellulose (HPMC) on the crystal habit properties of carbamazepine in sustained release matrix tablets and in aqueous solutions was investigated using differential scanning calorimetry (DSC), X-ray powder diffraction and scanning electron microscopy (SEM). The results suggest that HPMC inhibits the transformation of carbamazepine to carbamazepine dihydrate in the gel layer of hydrated tablets and in aqueous solutions (depending on HPMC concentration), participates in its crystallization process and induces amorphism of carbamazepine crystals. The mechanism which explains these effects envisages the polymer serving as a template or microsubstrate for nucleation in the crystallization process. We assume that the interaction between the drug and polymer occurs by hydrogen bonding. The hydroxyl groups of the polymer may attach to the drug at the site of water binding, and thus its transformation to the dihydrate form, is inhibited. A more specific interaction involves structural matching (similar bond spacing distances) between inter-atomic distances in the crystal lattice of carbamazepine dimer and intra-atomic distances along the polymer chain.
More Related Videos
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Oral Drug Delivery Systems: Continuous-Release Systems

